ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Alexion nabs potential $1B indication for Soliris, but it'll have to take on Roche's cheaper Rituxan
July 04, 2019In an effort to protect its blockbuster Soliris, Alexion has employed a double strategy of nabbing additional approvals and positioning follow-up drug Ultomiris to switch over sales. Alexion added another indication this week that could rake in $1 billion
Pharma Sources Insight January 2025
